EUROFINS SCIENT. And VIRBAC Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

(VIANEWS) – EUROFINS SCIENT. (ERF.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.

Financial Asset Price Forward Dividend Yield Return on Equity
EUROFINS SCIENT. (ERF.PA) €59.08 1.76% 6.16%
VIRBAC (VIRP.PA) €346.00 0.37% 13.84%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. EUROFINS SCIENT. (ERF.PA)

1.76% Forward Dividend Yield and 6.16% Return On Equity

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

Earnings Per Share

As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €1.57.

PE Ratio

EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 37.63. Meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.16%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 6.51B for the twelve trailing months.

More news about EUROFINS SCIENT..

2. VIRBAC (VIRP.PA)

0.37% Forward Dividend Yield and 13.84% Return On Equity

Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.

Earnings Per Share

As for profitability, VIRBAC has a trailing twelve months EPS of €14.12.

PE Ratio

VIRBAC has a trailing twelve months price to earnings ratio of 24.5. Meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.84%.

More news about VIRBAC.

Leave a Reply

Your email address will not be published. Required fields are marked *